RTP Mobile Logo
Exploring the Multidisciplinary Management of Localized Non-Small Cell Lung Cancer with EGFR Mutation (Webinar Video Proceedings)
Released May 2021

Proceedings from a satellite symposium held during the AATS 101st Annual Meeting. Featuring perspectives from Drs Harvey I Pass, Lecia V Sequist and Helena Yu. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and thoracic surgeons involved in the treatment of lung cancer.

    LEARNING OBJECTIVES

    • Assess the benefits, risks and long-term outcomes anticipated with the use of adjuvant therapy in the management of Stage IB to IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding current therapeutic recommendations.
    • Consider the prevalence of EGFR alterations found in patients with localized NSCLC, and refine diagnostic algorithms in clinical practice to ensure more accurate identification of individuals harboring these genetic abnormalities.
    • Appreciate available Phase III findings supporting the efficacy of adjuvant osimertinib for NSCLC with an EGFR mutation, and identify patients for whom treatment with this recently FDA-approved strategy may be appropriate.
    • Recognize the adverse events associated with osimertinib for patients with early-stage NSCLC, and understand the supportive strategies available to minimize and manage these toxicities.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Harvey I Pass, MD
    Stephen E Banner Professor of Thoracic Oncology
    Vice-Chairman, Research
    Department of Cardiothoracic Surgery
    Director, General Thoracic Surgery
    NYU Langone Medical Center
    New York, New York

    No relevant conflicts of interest to disclose.

    Lecia V Sequist, MD, MPH
    Director, Center for Innovation in Early Cancer Detection
    Massachusetts General Hospital Cancer Center
    The Landry Family Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Patent Pending: In conjunction with Blueprint Medicines.

    Helena Yu, MD
    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Lilly, Novartis, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Release date: May 2021
    Expiration date: May 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):